A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Yu, Evan Y.
Yazji, Salim
Katz, Yisrael
Coates, Elisabeth
Nordquist, Luke T.
Vandross, Andrae Lavon
Salkeni, Mohamad Adham
Lang, Joshua Michael
Nelson, Peter
Breitmeyer, James Bradley
Fong, Lawrence
De Bono, Johann S.
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Oncternal Therapeut Inc, San Diego, CA USA
[3] Urol Canc Ctr PC, Omaha, NE USA
[4] NEXT Oncol, Austin, TX USA
[5] NEXT Oncol, Fairfax, VA USA
[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[7] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA USA
[8] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-225-3248-4005; 283-183-180-5577-2829-12292; 613-225-325; 261-436; 130-540-543; 283-183-180; 298-145-222-184-1022-9124; 7; 5; 4; 3; 2; 60; 2946; 1917; 162; 1; 38092-18135; 38092-18313; 38092-21759; 9;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS241 / TPS241
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
    Yu, Evan Y.
    Nordquist, Luke
    Yazji, Salim
    Katz, Yisrael
    Coates, Elisabeth
    Vandross, Andrae Lavon
    Salkeni, Mohamad Adham
    Emamekhoo, Hamid
    Heath, Elisabeth I.
    De Kouchkovsky, Ivan
    Lang, Joshua Michael
    Nelson, Peter
    Breitmeyer, James Bradley
    Fong, Lawrence
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [3] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Won Kim
    Charles J Ryan
    Current Treatment Options in Oncology, 2012, 13 : 189 - 200
  • [4] Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Conteduca, Vincenza
    Jayaram, Anuradha
    Romero-Laorden, Nuria
    Wetterskog, Daniel
    Salvi, Samanta
    Gurioli, Giorgia
    Scarpi, Emanuela
    Castro, Elena
    Marin-Aguilera, Mercedes
    Lolli, Cristian
    Schepisi, Giuseppe
    Maugeri, Antonio
    Wingate, Anna
    Farolfi, Alberto
    Casadio, Valentina
    Medina, Ana
    Puente, Javier
    Mendez Vidal, Ma Jose
    Morales-Barrera, Rafael
    Villa-Guzman, Jose C.
    Hernando, Susana
    Rodriguez-Vida, Alejo
    Gonzalez-del-Alba, Aranzazu
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Olmos, David
    Attard, Gerhardt
    De Giorgi, Ugo
    EUROPEAN UROLOGY, 2019, 75 (03) : 368 - 373
  • [5] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Kim, Won
    Ryan, Charles J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 189 - 200
  • [6] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tomohiro Tsuchiya
    Keiichiro Imanaka
    Yuki Iwaki
    Ryo Oyama
    Katsuyoshi Hashine
    Akito Yamaguchi
    Hiroji Uemura
    International Journal of Clinical Oncology, 2019, 24 : 1596 - 1604
  • [7] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tsuchiya, Tomohiro
    Imanaka, Keiichiro
    Iwaki, Yuki
    Oyama, Ryo
    Hashine, Katsuyoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) : 1596 - 1604
  • [8] ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer.
    Kallio, Pekka
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Malmstrom, Chira
    Mustonen, Mika V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [9] A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Morris, Michael J.
    Danila, Daniel Costin
    Slovin, Susan F.
    Steinbrecher, Jill Elise
    Arauz, Gabrielle
    Curley, Tracy
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Fleisher, Martin
    Landa, Jonathan
    Fox, Josef J.
    Larson, Steven M.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer Beyond the Androgen Receptor
    Loriot, Yohann
    Zoubeidi, Amina
    Gleave, Martin E.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 517 - +
12345